Mizuki Nishino

Mizuki Nishino

Auto-generated profile, based on publicly available information

Mizuki Nishino

Department of Radiology, Brigham and Women’s Hospital, 75 Francis St, Boston MA 02215

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2017 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MNMizuki Nishino
Mizuki Nishino
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
HHHiroto Hatabu
Hiroto Hatabu
FHF. Stephen Hodi
F. Stephen Hodi

15 July 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MNMizuki Nishino
Mizuki Nishino
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
MGMaria Gargano
Maria Gargano
MSMargaret Suda
Margaret Suda
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
FHF. Stephen Hodi
F. Stephen Hodi
Purpose: Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in patients with advanced melanoma treated with ipilimumab. Experimental Design: Fifty-seven patients with advanced melanoma treated with ipilimumab in a phase II, expanded access trial were studied. Bidimensional tumor measurement records prospectively conducted during the trial were reviewed to generate a second set of measurements using unidimensional, longest diameter measurements. The percent changes of measurements at follow-up, best overall response, and time-to-progression (TTP) were compared between bidimensional and unidimensional irRC. Interobserver variability for bidimensional and unidimensional measurements was assessed in 25 randomly selected patients. Results: The percent changes at follow-up scans were highly concordant between the 2 criteria (Spearman r: 0.953–0.965, first to fourth follow-up). The best immune-related response was highly concordant between the 2 criteria (κw = 0.881). TTP was similar between the bidimensional and unidimensional assessments (progression-free at 6 months: 70% vs. 81%, respectively). The unidimensional measurements were more reproducible than bidimensional measurements, with the 95% limits of agreement of (−16.1%, 5.8%) versus (−31.3%, 19.7%), respectively. Conclusion: irRC using the unidimensional measurements provided highly concordant response assessment compared with the bidimensional irRC, with less measurement variability. The use of unidimensional irRC is proposed to assess response to immunotherapy in solid tumors, given its simplicity, higher reproducibility, and high concordance with the bidimensional irRC. Clin Cancer Res; 19(14); 3936–43. ©2013 AACR.

15 December 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MNMizuki Nishino
Mizuki Nishino
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
MAMark M. Awad
Mark M. Awad
LSLynette M. Sholl
Lynette M. Sholl
JMJennifer A. Maattala
Jennifer A. Maattala
FHF. Stephen Hodi
F. Stephen Hodi
Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor–related pneumonitis in advanced cancer patients. Experimental Design: Among patients with advanced melanoma, lung cancer, or lymphoma treated in trials of nivolumab, we identified those who developed pneumonitis. Chest CT scans were reviewed to assess extent, distribution, and radiographic patterns of pneumonitis. Results: Among 170 patients treated in 10 different trials of nivolumab, 20 patients (10 melanoma, 6 lymphoma, and 4 lung cancer) developed pneumonitis. Five patients received nivolumab monotherapy, and 15 received combination therapy. The median time from therapy initiation to pneumonitis was 2.6 months. Radiographic pattern was cryptogenic organizing pneumonia (COP) in 13, nonspecific interstitial pneumonia (NSIP) in 3, hypersensitivity pneumonitis (HP) in 2, and acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) in 2 patients. The AIP/ARDS pattern had the highest grade, followed by COP, whereas NSIP and HP had lower grade (median grade: 3, 2, 1, 1, respectively; P = 0.006). The COP pattern was most common in all tumors and treatment regimens. Most patients (17/20; 85%) received corticosteroids, and 3 (15%) also required infliximab. Seven patients restarted nivolumab therapy; 2 of them developed recurrent pneumonitis and were successfully retreated with corticosteroids. One of the patients experienced a pneumonitis flare after completion of corticosteroid taper without nivolumab retreatment. Conclusions: PD-1 inhibitor–related pneumonitis showed a spectrum of radiographic patterns, reflecting pneumonitis grades. COP was the most common pattern across tumor types and therapeutic regimens. Most patients were successfully treated with corticosteroids. Recurrent pneumonitis and pneumonitis flare were noted in a few patients. Clin Cancer Res; 22(24); 6051–60. ©2016 AACR. See related commentary by Castanon, p. 5956

16 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
MNMizuki Nishino
Mizuki Nishino
LSLynette M. Sholl
Lynette M. Sholl
HHHiroto Hatabu
Hiroto Hatabu
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
FHF. Stephen Hodi
F. Stephen Hodi
Among three patients with melanoma receiving anti–PD-1 antibodies, the use of checkpoint blockers led to the development of serious autoimmune pneumonitis, a potentially lethal complication.

1 August 2010 in American Journal of Roentgenology
Verified
Journal Article
Closed access
MNMizuki Nishino
Mizuki Nishino
JJJyothi P. Jagannathan
Jyothi P. Jagannathan
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
AAAnnick D. Van Den Abbeele
Annick D. Van Den Abbeele
OBJECTIVE. The objectives of this article are to review the new Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1, highlighting the major changes in the new version compared with the original RECIST guideline (version 1.0), and to present case examples with representative imaging.CONCLUSION. Familiarity with the revised RECIST is essential in day-to-day oncologic imaging practice to provide up-to-date service to oncologists and their patients. Some of the changes in the revised RECIST affect how radiologists select, measure, and report target lesions.

1 October 2015 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
STSree Harsha Tirumani
Sree Harsha Tirumani
NRNikhil H. Ramaiya
Nikhil H. Ramaiya
AKAbhishek Keraliya
Abhishek Keraliya
NBNancy D. Bailey
Nancy D. Bailey
POPatrick A. Ott
Patrick A. Ott
MNMizuki Nishino
Mizuki Nishino
Ipilimumab is a promising novel immunotherapy agent and is associated with a variety of immune-related adverse events (irAE). The purpose of this study was to investigate the manifestations of irAEs on body imaging in patients with advanced melanoma treated with ipilimumab. One-hundred forty-seven patients with advanced melanoma (59 women, 88 men; median age, 64.5 years) treated with ipilimumab were studied. All patients had the baseline and at least one follow-up chest/abdomen/pelvis CT or PET/CT during therapy, which were reviewed by a consensus of two radiologists blinded to the clinical data. Findings indicative of individual types of irAEs were assessed, including thyroiditis, sarcoid-like lymphadenopathy, pneumonitis, hepatitis, pancreatitis, and colitis. Among the 147 patients, 46 (31%) had radiologically identified irAEs. The time interval from the initiation of therapy to the development of irAEs was less than 3 months in 76% (35 of 46) of the patients (range, 0.2–9.1 months). Clinical characteristics did not differ between patients with and without irAEs (P > 0.18). Among the individual types of irAEs, colitis was most common (n = 28; 19%), followed by sarcoid-like lymphadenopathy (n = 8; 5%) and pneumonitis (n = 8; 5%). Hepatitis (n = 3), thyroiditis (n = 2), and pancreatitis (n = 1) were less common. The resolution of irAEs was noted in 32 of 36 patients (89%) with further follow-up scans, with a median time of 2.3 months after the detection of irAE. In conclusion, irAEs were noted on body imaging in 31% of patients with melanoma treated with ipilimumab. Colitis was the most common, followed by sarcoid-like lymphadenopathy and pneumonitis. The results call for an increased awareness of irAEs, given the expanding role of cancer immunotherapy. Cancer Immunol Res; 3(10); 1185–92. ©2015 AACR.